Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 10:39 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 53 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Cyclosporin solution Clear all
Terminated Phase 3 Interventional

CIS001 Extension Study of Cyclosporine Inhalation Solution

NCT00938236
View directory record Official record
Conditions
Lung Transplant
Interventions
Cyclosporine Inhalation Solution (CIS)
Drug
Lead sponsor
APT Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
15
States / cities
Los Angeles, California • San Francisco, California • Stanford, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2012 · Synced Oct 21, 2026, 10:39 AM EDT
Recruiting Phase 4 Interventional

Efficacy of Vevye Ophthalmic Solution for the Treatment of Meibomian Gland Dysfunction

NCT07224529
View directory record Official record
Conditions
Meibomian Gland Dysfunction (MGD)
Interventions
Vevye(Cyclosporine 0.1% Ophthalmic Solution)
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 21, 2026, 10:39 AM EDT
Terminated Not applicable Interventional Results available

The Effects of Cyclosporin A in a Low Humidity Environment, on the Ocular Surface

NCT02199964
View directory record Official record
Conditions
Dry Eye
Interventions
Cyclosporin 0.05% emulsion, Endura, Refresh artificial tears
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 20, 2020 · Synced Oct 21, 2026, 10:39 AM EDT
Completed Phase 3 Interventional Results available

CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease in Subjects Who Completed CYS-004

NCT04523142
View directory record Official record
Conditions
Dry Eye Disease (DED)
Interventions
CyclASol Ophthalmic Solution
Drug
Lead sponsor
Novaliq GmbH
Industry
Eligibility
18 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
14
States / cities
Los Angeles, California • Newport Beach, California • Carmel, Indiana + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2023 · Synced Oct 21, 2026, 10:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Drug-Drug Interaction Study to Examine the Impact of Itraconazole and Cyclosporine on PF-07081532 Pharmacokinetics in Overweight or Obese Adults

NCT05745701
View directory record Official record
Conditions
Healthy
Interventions
PF-07081532, Cyclosporine, Itraconazole
Drug · Device
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 23, 2024 · Synced Oct 21, 2026, 10:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn if the Study Medicines Called Itraconazole and Cyclosporine Change How the Body Processes the Other Study Medicine Called Danuglipron in Healthy Adults.

NCT06541678
View directory record Official record
Conditions
Healthy
Interventions
Danuglipron, Cyclosporine, Itraconazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 3, 2025 · Synced Oct 21, 2026, 10:39 AM EDT
Completed Phase 2 Interventional Results available

A Phase II Dose-escalation Study Characterizing the PK of Eltrombopag in Pediatric Patients With Previously Untreated or Relapsed Severe Aplastic Anemia or Recurrent Aplastic Anemia

NCT03025698
View directory record Official record
Conditions
Aplastic Anemia
Interventions
Eltrombopag, hATG, CsA
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
1 Year to 18 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
12
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Aurora, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 21, 2026, 10:39 AM EDT
Terminated Phase 2 Interventional Results available

Pilot Study of a Homeopathic Therapy in Combination With Cyclosporin (Restasis) in the Treatment of Dry Eye Disease

NCT01072526
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
Euphrasia-based homeopathic therapy, Cyclosporin solution
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
21 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 21, 2026, 10:39 AM EDT
Completed Phase 3 Interventional Results available

ESSENCE 2: CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)

NCT04523129
View directory record Official record
Conditions
Dry Eye Disease
Interventions
CyclASol topical ocular, eye drops, Vehicle topical ocular, eye drops
Drug
Lead sponsor
Novaliq GmbH
Industry
Eligibility
18 Years and older
Enrollment
834 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
27
States / cities
Phoenix, Arizona • Los Angeles, California • Newport Beach, California + 23 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2023 · Synced Oct 21, 2026, 10:39 AM EDT
Completed Phase 2 Interventional Results available

Study of Cyclosporine in Post-LASIK Patients

NCT00991458
View directory record Official record
Conditions
Laser In Situ Keratomileusis
Interventions
Cyclosporine 0.010% eye drops, Cyclosporine 0.005% eye drops, Placebo (Vehicle for Cyclosporine)
Drug
Lead sponsor
Allergan
Industry
Eligibility
21 Years to 50 Years
Enrollment
621 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 11, 2013 · Synced Oct 21, 2026, 10:39 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

A Study to Explore Signs, Symptoms, and Biomarkers in Dry Eye Disease Participants Following Anti-inflammatory Treatment

NCT07025811
View directory record Official record
Conditions
Dry Eye Disease
Interventions
Vevye®, Xiidra®
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
378 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
8
States / cities
Newport Beach, California • Louisville, Kentucky • Andover, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 21, 2026, 10:39 AM EDT
Completed Phase 4 Interventional Results available

Effect of Cequa™ in Subjects With Dry Eye Disease

NCT04357795
View directory record Official record
Conditions
Dry Eye Disease
Interventions
CequaTM (Cyclosporine 0.09%) ophthalmic solution
Drug
Lead sponsor
Sun Pharmaceutical Industries Limited
Industry
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
5
States / cities
Fort Myers, Florida • Jacksonville, Florida • Panama City, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2024 · Synced Oct 21, 2026, 10:39 AM EDT
Completed Phase 3 Interventional Results available

Phase 3 Study of OTX-101 in the Treatment of Keratoconjunctivitis Sicca

NCT02688556
View directory record Official record
Conditions
Keratoconjunctivitis Sicca
Interventions
cyclosporine, vehicle of OTX-101
Drug
Lead sponsor
Sun Pharmaceutical Industries Limited
Industry
Eligibility
18 Years and older
Enrollment
745 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
3
States / cities
Rancho Cordova, California • Edgewood, Kentucky • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 29, 2022 · Synced Oct 21, 2026, 10:39 AM EDT
Completed Phase 2 Interventional Results available

Study Comparing the Safety and Efficacy of Belatacept With That of Cyclosporine in Patients With a Transplanted Kidney

NCT00035555
View directory record Official record
Conditions
Graft Rejection, Kidney Transplantation, Renal Transplantation
Interventions
Belatacept, Cyclosporine, Mycophenolate mofetil (MMF), Corticosteroids
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2012
U.S. locations
12
States / cities
San Francisco, California • Atlanta, Georgia • Baltimore, Maryland + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2014 · Synced Oct 21, 2026, 10:39 AM EDT
Completed Phase 2 Interventional Results available

Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation

NCT03434730
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Acute Leukemia, Myelodysplastic Syndromes, Myelodysplastic-Myeloproliferative Diseases, Myeloproliferative Disorder, Non Hodgkin Lymphoma, Hodgkin Lymphoma, Leukemia
Interventions
Total Body Irradiation, Cyclosporine, Mycophenolate Mofetil, Tocilizumab, Filgrastim
Radiation · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 21, 2026, 10:39 AM EDT
Completed Not applicable Interventional

Will Restasis Eye Drops Increase Your Chance of Having a Successful Surgery?

NCT00405431
View directory record Official record
Conditions
Glaucoma
Interventions
Restasis, Endura (artificial tears)
Drug
Lead sponsor
Wills Eye
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 22, 2016 · Synced Oct 21, 2026, 10:39 AM EDT
Completed Phase 4 Interventional

CEQUA for Sjogren's Syndrome Dry Eye

NCT04835623
View directory record Official record
Conditions
Dry Eye, Dry Eye Syndromes, Sjogren's Syndrome
Interventions
Cyclosporine 0.09% Ophthalmic Solution
Drug
Lead sponsor
Center for Ophthalmic and Vision Research, LLC
Other
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Manhattan, New York
Source: ClinicalTrials.gov public record
Updated Apr 16, 2024 · Synced Oct 21, 2026, 10:39 AM EDT
Completed Phase 3 Interventional

Study of Cyclosporine Inhalation Solution (CIS) in Improving Bronchiolitis Obliterans Syndrome-Free Survival Following Lung Transplantation

NCT00755781
View directory record Official record
Conditions
Lung Transplant
Interventions
Cyclosporine Inhalation Solution (CIS)
Drug
Lead sponsor
APT Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
284 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
18
States / cities
Los Angeles, California • San Francisco, California • Stanford, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2012 · Synced Oct 21, 2026, 10:39 AM EDT
Completed Phase 3 Interventional Results available

Study of Belatacept in Subjects Who Are Undergoing a Renal Transplant

NCT00114777
View directory record Official record
Conditions
Renal Transplantation
Interventions
Cyclosporin A, Belatacept Less Intensive Regimen (LI), Belatacept More Intensive Regimen (MI)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
595 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
28
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2017 · Synced Oct 21, 2026, 10:39 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Novel Use of Cyclosporine Ophthalmic Emulsion 0.05% in a PROSE Device

NCT04918823
View directory record Official record
Conditions
Ocular Surface Disease
Interventions
Restasis
Drug
Lead sponsor
Boston Sight
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Needham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 13, 2025 · Synced Oct 21, 2026, 10:39 AM EDT
Completed Phase 2 Interventional

Study Evaluating the Efficacy of Administration of Cyclosporine (Low Dose and High Dose) and Prednisolone Acetate Compared to Its Components and Vehicle in Patients With Allergic Conjunctivitis

NCT01120132
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
CsA high dose, CsA low dose, PA, Placebo
Drug
Lead sponsor
Fovea Pharmaceuticals SA
Industry
Eligibility
18 Years and older
Enrollment
716 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 9, 2012 · Synced Oct 21, 2026, 10:39 AM EDT
Completed Phase 2Phase 3 Interventional Results available

CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)

NCT03292809
View directory record Official record
Conditions
Dry Eye Disease
Interventions
CyclASol topical ocular, eye drops, Vehicle topical ocular, eye drops
Drug
Lead sponsor
Novaliq GmbH
Industry
Eligibility
18 Years and older
Enrollment
328 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
9
States / cities
Newport Beach, California • Torrance, California • Indianapolis, Indiana + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2022 · Synced Oct 21, 2026, 10:39 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Safety and Efficacy of Cenegermin (Oxervate®) vs Vehicle in Severe Sjogren's Dry Eye Disease

NCT05136170
View directory record Official record
Conditions
Dry Eye Disease
Interventions
Cenegermin, Vehicle
Drug · Other
Lead sponsor
Dompé Farmaceutici S.p.A
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
7
States / cities
Glendale, California • Baltimore, Maryland • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2025 · Synced Oct 21, 2026, 10:39 AM EDT
Enrolling by invitation Early Phase 1 Interventional

Cyclosporine Vs Steroids in DRESS

NCT04988256
View directory record Official record
Conditions
DRESS Syndrome, Drug-Induced Hypersensitivity Syndrome
Interventions
Cyclosporine, Methylprednisolone and Prednisone
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 30, 2025 · Synced Oct 21, 2026, 10:39 AM EDT